Researchers participating in HCRN GI14-198, recently reported findings in the European Journal of Cancer. The study was a phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients.

Researchers participating HCRN BRE21-516, also known as BRIDGET, had their work featured as a Trials in Progress abstract at the Society for NeuroOncology Annual Summit. The study focuses on secondary brain metastases prevention after isolated intracranial progression on trastuzumab/pertuzumab or T-DM1 in patients with advanced human epidermal growth factor receptor 2+ breast cancer with the addition of tucatinib.

HCRN LUN13-175 recently had its findings published in The Oncologist. Led by Nisha Mohindra, MD of Northwestern, this trial was a phase I/II trial of carboplatin, Nab-paclitaxel, and pembrolizumab for advanced non-small cell lung cancer (NSCLC).

During the 2023 ASCO Annual Meeting, Patrick J. Loehrer, MD, FACP, FASCO, received the ASCO Humanitarian Award in recognition of his work personifying ASCO’s mission and values as well as providing service and leadership both at home and abroad.

Three Hoosier Cancer Research Network (HCRN) investigator-initiated clinical trials were highlighted during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago.

Hoosier Cancer Research Network (HCRN) will have an exhibitors booth at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. Visit Booth #28115 to talk with our highly qualified staff about our 35 years of experience managing oncology/hematology multi-center clinical trials.

Hoosier Cancer Research Network urothelial cancer study was highlighted during the 2023 ASCO Genitourinary Cancers Symposium in San Francisco. In a poster and rapid abstract session presentation during the 2023 ASCO Genitourinary Cancers Symposium. Jason Brown, MD, PhD, of University Hospitals Seidman Cancer Center presented the results of HCRN GU14-188, a Phase Ib/II trial of neoadjuvant pembrolizumab and chemotherapy for T2-4aNOMO urothelial cancer.

Researchers participating in the study known as ADAPT-BLADDER, or HCRN GU16-243, recently reported preliminary findings in the journal European Urology. The study evaluated the safety and preliminary efficacy of anti-PD-L1 directed therapy with durvalumab (cohort 1), durvalumab plus Bacillus Calmette-Guerin (BCG) (cohort 2) and durvalumab plus external beam radiation therapy (EBRT) (cohort 3).

It is with heavy hearts we share the passing of Hoosier Cancer Research Network Board Member Alesha Arnold, RN.

Alesha was a breast oncology research nurse at the IU School of Medicine and supported the Clinical Trials Office at the IU Melvin and Bren Simon Cancer Center. Alesha worked with Clarian Health from 1997 to 2003 and served as a Clinical Research Nurse in gynecological cancer and breast cancer from 2008 to 2023. Alesha was also a patient at the IU Melvin and Bren Simon Cancer Center from 2019 to 2023.

Hoosier Cancer Research Network highlights Bently Doonan, MD, MS, oncologist and assistant professor in the division of hematology & oncology at the university of Florida College of Medicine.

Three Hoosier Cancer Research Network genitourinary studies were featured during the American Society of Clinical Oncology Genitourinary (GU) Cancers Symposium in San Francisco, CA on February 16-18, 2023.

Three Hoosier Cancer Research Network (HCRN) investigator-initiator clinical trials will be highlighted during the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco, CA.

Hoosier Cancer Research Network (HCRN) is currently seeking a part-time communications intern. Students working toward a college degree in Marketing/Communications, Advertising, Public Relations or English are preferred.

Hoosier Cancer Research Network highlights Russell Pachynski, MD, genitourinary medical oncologist and associate professor of Medicine, Division of Medical Oncology, at Washington University School of Medicine.

Hoosier Cancer Research Network (HCRN) announced today that Brian Stemme has been appointed Chief Executive Officer. Stemme, widely regarded as a champion of Indiana’s life sciences industry, will succeed Executive Director Cyndi Burkhardt, RN, who announced her retirement earlier this year. Stemme will assume responsibilities on Monday, August 29.

Hoosier Cancer Research Network highlights Sarah Sammons, MD a medical oncologist at Duke Cancer Center.

Hoosier Cancer Research Network highlights Richard Hall, MD, MS, a medical oncologist at University of Virginia Cancer Center. Dr. Hall is a member of the HCRN Thoracic Clinical Trial Working Group. Read More

Meet Hatim Sabaawy, MD, PhD

Hatim Sabaawy, MD, PhD, of the University of Colorado Cancer Center is the Director of Personalized Medicine in the Division of Medical Oncology at the CU School of Medicine. Dr. Sabaawy is responsible for fostering translational research activities across the academic and clinical partner institutions of the CU Cancer Center, including Children’s Hospital Colorado and UC Health. Read More

Hoosier Cancer Research Network highlights Pashtoon Kasi, MD, MS, a medical oncologist at Weil Cornell Medicine. Dr. Kasi is a member of the HCRN Gastrointestinal Clinical Trial Working Group. Read More

Four Hoosier Cancer Research Network (HCRN) investigator-initiated clinical trials were highlighted during the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
HCRN investigators presented one poster and three trials in progress posters during the 2022 ASCO annual meeting. Read More